Avanir Pharmaceuticals Receives $30M Debt Facility

Avanir Pharmaceuticals, Inc., an Aliso Viejo, CA-based biopharmaceutical company focused on bringing medicines to patients with central nervous system disorders, has received a $30m debt facility.

The financing was led by Oxford Finance LLC, with participation from Silicon Valley Bank.

The company intends to use the proceeds for the expansion of its product line and working capital.

Led by Keith Katkin, president and CEO, Avanir already has an FDA-approved drug, NUEDEXTA® (dextromethorphan HBr and quinidine sulfate), which treats pseudobulbar affect.



Join the discussion